Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis
Immune Tolerance and Inflammation in ABPA in Patients with Cystic Fibrosis
批准号:
8118860
负责人:
JAY K KOLLS
金额:
$51.6万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AffectAllergicAllergic Bronchopulmonary AspergillosisAllergic DiseaseAntibodiesAntigen-Presenting CellsAntigensAspergillusAspergillus fumigatusAsthmaAzolesBindingBiological AssayBloodBronchiectasisCD4 Positive T LymphocytesCaspofunginCell Culture SystemCellsCoculture TechniquesCystic FibrosisDataDendritic CellsDevelopmentDiagnosisFibrosisFlow CytometryFoxesGenerationsGlucansHigh PrevalenceHypersensitivityIL2RA geneIgEImmune ToleranceIndividualInflammationInflammatoryInflammatory ResponseInterleukin-10Interleukin-13Interleukin-4Interleukin-5KnowledgeLaboratoriesLigandsLigaseLungLung diseasesMediatingMicroscopyModelingMusOrganismPatientsPhenotypePlayPopulationProductionRegulatory T-LymphocyteRoleSputumStimulusSurfaceSwellingT cell responseT-LymphocyteTestingTimeUniversitiesVoriconazoleWheezingWorkadaptive immunityatopybasebeta-1,3-glucanbeta-Glucansbeta-glucan receptorcystic fibrosis patientscytokinedectin 1human subjectinhibitor/antagonistmacrophagemonocyteneutralizing antibodyneutrophilperipheral bloodreceptorresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic disease characterized clinically by wheezing,
pulmonary infiltrates, bronchiectasis, and fibrosis that affects patients with asthma and cystic fibrosis (CF). In
patients with ABPA, immunological responses to a variety of Aspergillus fumigatus (Af) antigens result in a
heightened Th2 response and an elevated immunoglobulin E (IgE) level. At our CF Center ABPA affects 7%
of the CF population however over 30% are colonized with Af. Preliminary data in our laboratory
demonstrates that Dectin-1, a beta-glucan receptor expressed in dendritic cells and macrophages is required
for recognition of swollen conidia; a form of Af that precedes hyphal development. Preliminary data suggest
that Dectin-1 is also required for Th2 response in CF patients with ABPA. Additionally patients with Af
colonization without ABPA have elevated antigen specific IL-10 responses which we propose is due the
development of regulatory T-cell response in these patients. Based on these data, we hypothesize that CF
patients with ABPA require monocyte/dendritic cell expression of dectin-1 for the presentation of specific
Aspergillus antigens (namely swollen conidia) as well as for Th2 cytokine elaboration. Moreover, we
hypothesize that a decreased in Treg cells is required for development of APBPA compared to CF patients
colonized with Aspergillus but no evidence of ABPA. To test these hypotheses, we propose the following
specific aims: Specific Aim 1: To test the hypothesis that CF patients with ABPA require Dectin-1 expression
on peripheral blood monocytes/dendritic cells and that binding of A. fumigatus to Dectin-1 will produce a
heightened inflammatory response in patients with ABPA compared to non-ABPA patients. Specific Aim 2:
To test the hypothesis that T cells from CF patients with ABPA will have decreased adaptive Treg function.
Specific Aim 3. To test the hypothesis that anti-fungals targeted against glucan synthetase block both proinflammatory
and Th2 cytokine induction in peripheral blood of patients with CF with ABPA. Understanding
these responses in ABPA will increase our knowledge regarding mechanisms of allergy vs. tolerance in
human subjects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tulane StARR Program
-
批准号:10608042
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2021
-
负责人:JAY K KOLLS
-
依托单位:
Tulane StARR Program
-
批准号:10318191
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2021
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:9981924
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10443796
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10227140
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
Immunotherapy of KPC Infection
-
批准号:10671653
-
项目类别:
-
资助金额:$48.64万
-
财政年份:2020
-
负责人:JAY K KOLLS
-
依托单位:
CD4_T-cell_Immunity_in_the_Lung
-
批准号:10321572
-
项目类别:
-
资助金额:$86.92万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
CD4_T-cell_Immunity_in_the_Lung
-
批准号:10559497
-
项目类别:
-
资助金额:$86.92万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
Training in CD4 T-cell Lung Immunity
-
批准号:9804524
-
项目类别:
-
资助金额:$9.37万
-
财政年份:2018
-
负责人:JAY K KOLLS
-
依托单位:
Generation of Novel Human Monoclonals for Lung Disease
-
批准号:9250044
-
项目类别:
-
资助金额:$6.79万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Generation of Novel Human Monoclonals for Lung Disease
-
批准号:9128312
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:10521311
-
项目类别:
-
资助金额:$47.95万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:9210593
-
项目类别:
-
资助金额:$24.87万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
-
批准号:10375091
-
项目类别:
-
资助金额:$51.07万
-
财政年份:2016
-
负责人:JAY K KOLLS
-
依托单位:
Th17 Cytokines and Lung Immunity
-
批准号:8990110
-
项目类别:
-
资助金额:$8.62万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
Th17 Cytokines and Lung Immunity
-
批准号:9193101
-
项目类别:
-
资助金额:$26.39万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
Core C RNA Sequencing and Bioinformatics
-
批准号:8853015
-
项目类别:
-
资助金额:$27.58万
-
财政年份:2015
-
负责人:JAY K KOLLS
-
依托单位:
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
-
批准号:8932653
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2014
-
负责人:JAY K KOLLS
-
依托单位:
Novel Macrolide Th17 Inhibitors
-
批准号:8130158
-
项目类别:
-
资助金额:$7.89万
-
财政年份:2011
-
负责人:JAY K KOLLS
-
依托单位:
Novel Macrolide Th17 Inhibitors
-
批准号:8255486
-
项目类别:
-
资助金额:$21.74万
-
财政年份:2011
-
负责人:JAY K KOLLS
-
依托单位:
海外基金